142 related articles for article (PubMed ID: 33148925)
1. Significance of ERCC1 and Hormonal Receptor Expression in Ovarian Cancer.
El-Moniem Elrawi DA; El Khodary AI; Nassar HR; Darwish AD; Khorshed EN
J Med Invest; 2020; 67(3.4):391-398. PubMed ID: 33148925
[TBL] [Abstract][Full Text] [Related]
2. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
[TBL] [Abstract][Full Text] [Related]
3. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Jakobsen A
Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
[TBL] [Abstract][Full Text] [Related]
4. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R
Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
[TBL] [Abstract][Full Text] [Related]
5. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
[TBL] [Abstract][Full Text] [Related]
6. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
7. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
Steffensen KD; Waldstrøm M; Jeppesen U; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2008; 18(4):702-10. PubMed ID: 17961161
[TBL] [Abstract][Full Text] [Related]
8. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Tian C; Muggia F; Dhir R; Armstrong DK; Bookman MA; Niedernhofer LJ; Deloia J; Birrer M; Krivak TC
Gynecol Oncol; 2012 May; 125(2):421-6. PubMed ID: 22261301
[TBL] [Abstract][Full Text] [Related]
9. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of excision repair cross complementing-1 and topoisomerase-1 expression in epithelial ovarian cancer.
Liu SC; Lin H; Huang CC; Chang Chien CC; Tsai CC; Ou YC; Fu HC; Liu JM; Ma YY
Taiwan J Obstet Gynecol; 2016 Apr; 55(2):213-9. PubMed ID: 27125404
[TBL] [Abstract][Full Text] [Related]
11. Expression of ERCC1 protein in biopsy specimen predicts survival in advanced ovarian cancer patients treated with platinum-based chemotherapy.
Milovic-Kovacevic M; Srdic-Rajic T; Radulovic S; Bjelogrlic S; Gavrilovic D
J BUON; 2011; 16(4):708-14. PubMed ID: 22331726
[TBL] [Abstract][Full Text] [Related]
12. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy.
Ozcan MF; Dizdar O; Dincer N; Balcı S; Guler G; Gok B; Pektas G; Seker MM; Aksoy S; Arslan C; Yalcin S; Balbay MD
Urol Oncol; 2013 Nov; 31(8):1709-15. PubMed ID: 22863869
[TBL] [Abstract][Full Text] [Related]
13. ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer.
Chebouti I; Kuhlmann JD; Buderath P; Weber S; Wimberger P; Bokeloh Y; Hauch S; Kimmig R; Kasimir-Bauer S
Oncotarget; 2017 Apr; 8(15):24303-24313. PubMed ID: 28388557
[TBL] [Abstract][Full Text] [Related]
14. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.
Li FY; Ren XB; Xie XY; Zhang J
Asian Pac J Cancer Prev; 2013; 14(12):7203-6. PubMed ID: 24460276
[TBL] [Abstract][Full Text] [Related]
16. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
[TBL] [Abstract][Full Text] [Related]
17. High ERCC1 expression is associated with platinum-resistance, but not survival in patients with epithelial ovarian cancer.
Du P; Wang Y; Chen L; Gan Y; Wu Q
Oncol Lett; 2016 Aug; 12(2):857-862. PubMed ID: 27446360
[TBL] [Abstract][Full Text] [Related]
18. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy.
Azuma K; Komohara Y; Sasada T; Terazaki Y; Ikeda J; Hoshino T; Itoh K; Yamada A; Aizawa H
Cancer Sci; 2007 Sep; 98(9):1336-43. PubMed ID: 17640298
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
20. Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis.
Zhang Z; Dou X; Yang H; Jia L; Qin K; Gao X; Yang B; Zhang W; Qin C; Zhang F; Shan B
Pathol Res Pract; 2020 Feb; 216(2):152794. PubMed ID: 31902551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
